易還財務投資(08079.HK):獲有效接納196.84萬股要約股份 延長要約截止時間
格隆匯5月18日丨易還財務投資(08079.HK)公佈,於2020年5月18日(星期一)(即要約的首個截止日期)下午四時正,要約人(a)已接獲13份有效接納,涉及合共1,968,412股要約股份,約佔於公告日期已發行股份總數的0.82%;及(b)並無接獲任何購股權要約的接納。於公告日期,接納股份連同要約人一致行動小組已擁有的股份合共為28,061,912股股份,約佔該公司已發行股本及投票權總額的11.67%。
為了給股東及購股權持有人更多時間以考慮要約,要約人已決定將要約的截止時間及日期由2020年5月18日下午四時正延長至2020年6月2日下午四時正。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.